Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Saved in:
| Title: | Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. |
|---|---|
| Authors: | Borse RH; Merck & Co., Inc., Kenilworth, NJ, USA., Ramakrishnan K; Merck & Co., Inc., Kenilworth, NJ, USA., Gandhi J; CHEORS, North Wales, PA, USA., Dhankhar P; CHEORS, North Wales, PA, USA., Chirovsky D; Merck & Co., Inc., Kenilworth, NJ, USA. |
| Source: | Journal of medical economics [J Med Econ] 2022 Jan-Dec; Vol. 25 (1), pp. 954-965. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35765888 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Borse+RH%22">Borse RH</searchLink>; Merck & Co., Inc., Kenilworth, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Ramakrishnan+K%22">Ramakrishnan K</searchLink>; Merck & Co., Inc., Kenilworth, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Gandhi+J%22">Gandhi J</searchLink>; CHEORS, North Wales, PA, USA.<br /><searchLink fieldCode="AU" term="%22Dhankhar+P%22">Dhankhar P</searchLink>; CHEORS, North Wales, PA, USA.<br /><searchLink fieldCode="AU" term="%22Chirovsky+D%22">Chirovsky D</searchLink>; Merck & Co., Inc., Kenilworth, NJ, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229892255%22">Journal of medical economics</searchLink> [J Med Econ] 2022 Jan-Dec; Vol. 25 (1), pp. 954-965. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9892255 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1941-837X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213696998%22">13696998 </searchLink><i>NLM ISO Abbreviation: </i>J Med Econ <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35765888 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/13696998.2022.2095826 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 954 Titles: – TitleFull: Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Borse RH – PersonEntity: Name: NameFull: Ramakrishnan K – PersonEntity: Name: NameFull: Gandhi J – PersonEntity: Name: NameFull: Dhankhar P – PersonEntity: Name: NameFull: Chirovsky D IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2022 Jan-Dec Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1941-837X Numbering: – Type: volume Value: 25 – Type: issue Value: 1 Titles: – TitleFull: Journal of medical economics Type: main |
| ResultId | 1 |
